Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.
Abstract: Replicon particles derived from Venezuelan equine encephalitis virus (VEE) are infectious non-propagating particles which act as a safe and potent systemic, mucosal, and cellular adjuvant when delivered with antigen. VEE and VEE replicon particles (VRP) can target multiple cell types including dendritic cells (DCs). The role of these cell types in VRP adjuvant activity has not been previously evaluated, and for these studies we focused on the contribution of DCs to the response to VRP. By analysis of VRP targeting in the draining lymph node, we found that VRP induced rapid recruitment of TNF-secreting monocyte-derived inflammatory dendritic cells. VRP preferentially infected these inflammatory DCs as well as classical DCs and macrophages, with less efficient infection of other cell types. DC depletion suggested that the interaction of VRP with classical DCs was required for recruitment of inflammatory DCs, induction of high levels of many cytokines, and for stable transport of VRP to the draining lymph node. Additionally, in vitro-infected DCs enhanced antigen-specific responses by CD4 and CD8 T cells. By transfer of VRP-infected DCs into mice we showed that these DCs generated an inflammatory state in the draining lymph node similar to that achieved by VRP injection. Most importantly, VRP-infected DCs were sufficient to establish robust adjuvant activity in mice comparable to that produced by VRP injection. These findings indicate that VRP infect, recruit and activate both classical and inflammatory DCs, and those DCs become mediators of the VRP adjuvant activity.
Published by Elsevier Ltd.
Publication Date: 2012-04-21 PubMed ID: 22531556PubMed Central: PMC3519277DOI: 10.1016/j.vaccine.2012.04.030Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- N.I.H.
- Extramural
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research focuses on understanding the role of dendritic cells (DCs) in adjuvant activity stimulated by Venezuelan equine encephalitis virus replicon particles (VRP). The researchers found that VRP-infected dendritic cells could induce an inflammatory state similar to actual VRP injection and were enough to stimulate robust adjuvant activity.
Understand the Role of Dendritic Cells in VRP Adjuvant Activity
- The study initially looks at the role of dendritic cells in bolstering the immune response to VRP. A replicon particle is an infectious but non-propagating particle derived from a virus, and in this case, the Venezuelan equine encephalitis virus.
- Previous studies have confirmed that VEE and its replicon particles can target multiple cell types, including dendritic cells. However, how these cells contribute to the adjuvant activity of VRP, the act of enhancing the body’s immune response to an antigen, hadn’t been studied in depth before.
Findings on Inflammatory Dendritic Cells
- Through analysis of VRP’s impact in the draining lymph node, it was discovered that VRP induces a rapid recruitment of TNF-secreting monocyte-derived inflammatory dendritic cells.
- The VRP was seen as infecting these inflammatory DCs, classical DCs, and macrophages, but it was less efficient in infecting other cell types. This suggested a preference of VRP for these cell categories.
- When dendritic cells were depleted, it suggested that VRP interaction with classical DCs was a requirement for recruiting inflammatory DCs, inducing several cytokines, and for secure transport of VRP to the draining lymph node.
Impact of VRP-infected Dendritic Cells
- The DCs infected with VRP in a lab setting were seen as enhancing the antigen-specific responses by CD4 and CD8 T cells. This implies that VRP-infected DCs play a significant role in bolstering immune response.
- By transferring VRP-infected DCs into mice, the researchers demonstrated that these DCs could generate an inflammatory state resembling that achieved by VRP injection.
- The most critical finding was that VRP-infected DCs were sufficient to establish robust adjuvant activity in the mice, comparable to the output of direct VRP injection.
Conclusion of the Research
- Based on these findings mentioned above, the study concluded that VRP infect and activate both classical and inflammatory DCs, and these DCs become mediators of VRP adjuvant activity.
- The role of infected DCs in mediating adjuvant activity provides potential for therapeutic applications in boosting immune responses in various medical scenarios.
Cite This Article
APA
Tonkin DR, Whitmore A, Johnston RE, Barro M.
(2012).
Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles.
Vaccine, 30(30), 4532-4542.
https://doi.org/10.1016/j.vaccine.2012.04.030 Publication
Researcher Affiliations
- Global Vaccines Inc, 7020 Kit Creek Rd, Ste. 240, PO Box 14827, Research Triangle Park, NC 27709, USA. dtonkin@globalvaccines.org
MeSH Terms
- Adjuvants, Immunologic / pharmacology
- Animals
- Antibodies, Viral / blood
- Cytokines / immunology
- Dendritic Cells / immunology
- Dendritic Cells / virology
- Encephalitis Virus, Venezuelan Equine / immunology
- Female
- Immunity, Cellular
- Immunity, Mucosal
- Inflammation / immunology
- Lymph Nodes / immunology
- Lymphocyte Activation
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C57BL
- Mice, Transgenic
- Replicon / immunology
- T-Lymphocytes / immunology
- Virion / immunology
Grant Funding
- U01 AI070976 / NIAID NIH HHS
- F32AI082894 / NIAID NIH HHS
- R01-AI088250 / NIAID NIH HHS
- R01 AI088250 / NIAID NIH HHS
- U01-AI070976 / NIAID NIH HHS
- F32 AI082894 / NIAID NIH HHS
References
This article includes 66 references
- Pulendran B. Modulating vaccine responses with dendritic cells and Toll-like receptors.. Immunol Rev 2004 Jun;199:227-50.
- Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity.. Curr Opin Immunol 2004 Feb;16(1):21-5.
- Barba-Spaeth G, Longman RS, Albert ML, Rice CM. Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes.. J Exp Med 2005 Nov 7;202(9):1179-84.
- Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work.. Immunity 2010 Oct 29;33(4):492-503.
- McKee AS, MacLeod MK, Kappler JW, Marrack P. Immune mechanisms of protection: can adjuvants rise to the challenge?. BMC Biol 2010 Apr 12;8:37.
- Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, Masopust D, Murali-Krishna K, Mahar PL, Edupuganti S, Lalor S, Germon S, Del Rio C, Mulligan MJ, Staprans SI, Altman JD, Feinberg MB, Ahmed R. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.. Immunity 2008 May;28(5):710-22.
- Ryman KD, Klimstra WB. Host responses to alphavirus infection.. Immunol Rev 2008 Oct;225:27-45.
- Craig CP, Reynolds SL, Airhart JW, Staab EV. Alterations in immune responses by attenuated Venezuelan equine encephalitis vaccine. I. Adjuvant effect of VEE virus infection in guinea pigs.. J Immunol 1969 May;102(5):1220-7.
- Howard RJ, Craig CP, Trevino GS, Dougherty SF, Mergenhagen SE. Enhanced humoral immunity in mice infected with attenuated Venezuelan equine encephalitis virus.. J Immunol 1969 Oct;103(4):699-707.
- Thompson JM, Whitmore AC, Konopka JL, Collier ML, Richmond EM, Davis NL, Staats HF, Johnston RE. Mucosal and systemic adjuvant activity of alphavirus replicon particles.. Proc Natl Acad Sci U S A 2006 Mar 7;103(10):3722-7.
- Thompson JM, Whitmore AC, Staats HF, Johnston RE. Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen.. Vaccine 2008 Aug 5;26(33):4267-75.
- Tonkin DR, Jorquera P, Todd T, Beard CW, Johnston RE, Barro M. Alphavirus replicon-based enhancement of mucosal and systemic immunity is linked to the innate response generated by primary immunization.. Vaccine 2010 Apr 19;28(18):3238-46.
- Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.. Virology 1997 Dec 22;239(2):389-401.
- Hubby B, Talarico T, Maughan M, Reap EA, Berglund P, Kamrud KI, Copp L, Lewis W, Cecil C, Norberg P, Wagner J, Watson A, Negri S, Burnett BK, Graham A, Smith JF, Chulay JD. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza.. Vaccine 2007 Nov 23;25(48):8180-9.
- Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, Esch RE, Negri S, Burnett B, Graham A, Olmsted RA, Chulay JD. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus.. Vaccine 2007 Oct 16;25(42):7441-9.
- Harrington PR, Yount B, Johnston RE, Davis N, Moe C, Baric RS. Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles.. J Virol 2002 Jan;76(2):730-42.
- Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE Jr. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats.. J Virol 2007 Dec;81(24):13710-22.
- Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.. Vaccine 2000 Aug 15;19(1):142-53.
- Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses.. Virology 2000 Dec 5;278(1):55-9.
- Carroll TD, Matzinger SR, Barro M, Fritts L, McChesney MB, Miller CJ, Johnston RE. Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.. Vaccine 2011 Jan 29;29(5):931-40.
- LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.. J Virol 2009 Apr;83(7):3212-27.
- Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge.. Nat Rev Immunol 2006 Feb;6(2):148-58.
- Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosal immunity.. Immunol Rev 2004 Jun;199:100-12.
- MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.. J Virol 2000 Jan;74(2):914-22.
- Nishimoto KP, Laust AK, Wang K, Kamrud KI, Hubby B, Smith JF, Nelson EL. Restricted and selective tropism of a Venezuelan equine encephalitis virus-derived replicon vector for human dendritic cells.. Viral Immunol 2007 Spring;20(1):88-104.
- Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM, Johnston RE, Serody JS. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.. Vaccine 2007 Sep 4;25(36):6604-12.
- Moran TP, Collier M, McKinnon KP, Davis NL, Johnston RE, Serody JS. A novel viral system for generating antigen-specific T cells.. J Immunol 2005 Sep 1;175(5):3431-8.
- Thompson JM, Nicholson MG, Whitmore AC, Zamora M, West A, Iwasaki A, Staats HF, Johnston RE. Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.. J Immunol 2008 Jul 1;181(1):574-85.
- Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, Connell MJ, Montefiori DC, Frelinger JA, Swanstrom R, Johnson PR, Johnston RE. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.. J Virol 2000 Jan;74(1):371-8.
- Davis NL, Powell N, Greenwald GF, Willis LV, Johnson BJ, Smith JF, Johnston RE. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone.. Virology 1991 Jul;183(1):20-31.
- Schäfer A, Brooke CB, Whitmore AC, Johnston RE. The role of the blood-brain barrier during Venezuelan equine encephalitis virus infection.. J Virol 2011 Oct;85(20):10682-90.
- Sai T, Milling SW, Mintz B. Freezing and thawing of bone marrow-derived murine dendritic cells with subsequent retention of immunophenotype and of antigen processing and presentation characteristics.. J Immunol Methods 2002 Jun 1;264(1-2):153-62.
- White LJ, Wang JG, Davis NL, Johnston RE. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5' untranslated region.. J Virol 2001 Apr;75(8):3706-18.
- León B, López-Bravo M, Ardavín C. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania.. Immunity 2007 Apr;26(4):519-31.
- Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development.. Nat Rev Immunol 2007 Jan;7(1):19-30.
- Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells.. Science 2010 Feb 5;327(5966):656-61.
- Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis.. Arterioscler Thromb Vasc Biol 2011 Jul;31(7):1506-16.
- Gordon S, Taylor PR. Monocyte and macrophage heterogeneity.. Nat Rev Immunol 2005 Dec;5(12):953-64.
- Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo.. Immunity 1999 Dec;11(6):753-61.
- Lin SL, Castaño AP, Nowlin BT, Lupher ML Jr, Duffield JS. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations.. J Immunol 2009 Nov 15;183(10):6733-43.
- Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells.. Annu Rev Immunol 2009;27:669-92.
- Tezuka H, Abe Y, Iwata M, Takeuchi H, Ishikawa H, Matsushita M, Shiohara T, Akira S, Ohteki T. Regulation of IgA production by naturally occurring TNF/iNOS-producing dendritic cells.. Nature 2007 Aug 23;448(7156):929-33.
- Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection.. Immunity 2003 Jul;19(1):59-70.
- Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T, Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA. In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens.. Immunity 2002 Aug;17(2):211-20.
- Shiow LR, Rosen DB, Brdicková N, Xu Y, An J, Lanier LL, Cyster JG, Matloubian M. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs.. Nature 2006 Mar 23;440(7083):540-4.
- Marshall JD, Heeke DS, Abbate C, Yee P, Van Nest G. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha.. Immunology 2006 Jan;117(1):38-46.
- Coro ES, Chang WL, Baumgarth N. Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection.. J Immunol 2006 Apr 1;176(7):4343-51.
- Thompson JM, Whitmore AC, Staats HF, Johnston R. The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.. Vaccine 2008 Sep 15;26(39):4998-5003.
- Beagley KW, Eldridge JH, Lee F, Kiyono H, Everson MP, Koopman WJ, Hirano T, Kishimoto T, McGhee JR. Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells.. J Exp Med 1989 Jun 1;169(6):2133-48.
- Coffman RL, Shrader B, Carty J, Mosmann TR, Bond MW. A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization.. J Immunol 1987 Dec 1;139(11):3685-90.
- Probst HC, Tschannen K, Odermatt B, Schwendener R, Zinkernagel RM, Van Den Broek M. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells.. Clin Exp Immunol 2005 Sep;141(3):398-404.
- Probst HC, van den Broek M. Priming of CTLs by lymphocytic choriomeningitis virus depends on dendritic cells.. J Immunol 2005 Apr 1;174(7):3920-4.
- GeurtsvanKessel CH, Willart MA, van Rijt LS, Muskens F, Kool M, Baas C, Thielemans K, Bennett C, Clausen BE, Hoogsteden HC, Osterhaus AD, Rimmelzwaan GF, Lambrecht BN. Clearance of influenza virus from the lung depends on migratory langerin+CD11b- but not plasmacytoid dendritic cells.. J Exp Med 2008 Jul 7;205(7):1621-34.
- Kassim SH, Rajasagi NK, Zhao X, Chervenak R, Jennings SR. In vivo ablation of CD11c-positive dendritic cells increases susceptibility to herpes simplex virus type 1 infection and diminishes NK and T-cell responses.. J Virol 2006 Apr;80(8):3985-93.
- Frank GM, Buela KA, Maker DM, Harvey SA, Hendricks RL. Early responding dendritic cells direct the local NK response to control herpes simplex virus 1 infection within the cornea.. J Immunol 2012 Feb 1;188(3):1350-9.
- Courreges MC, Burzyn D, Nepomnaschy I, Piazzon I, Ross SR. Critical role of dendritic cells in mouse mammary tumor virus in vivo infection.. J Virol 2007 Apr;81(8):3769-77.
- Simmons JD, White LJ, Morrison TE, Montgomery SA, Whitmore AC, Johnston RE, Heise MT. Venezuelan equine encephalitis virus disrupts STAT1 signaling by distinct mechanisms independent of host shutoff.. J Virol 2009 Oct;83(20):10571-81.
- Ryman KD, White LJ, Johnston RE, Klimstra WB. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis.. Viral Immunol 2002;15(1):53-76.
- Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.. J Immunol Methods 2003 Oct 1;281(1-2):65-78.
- Gardner CL, Burke CW, Tesfay MZ, Glass PJ, Klimstra WB, Ryman KD. Eastern and Venezuelan equine encephalitis viruses differ in their ability to infect dendritic cells and macrophages: impact of altered cell tropism on pathogenesis.. J Virol 2008 Nov;82(21):10634-46.
- Nakano H, Lin KL, Yanagita M, Charbonneau C, Cook DN, Kakiuchi T, Gunn MD. Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses.. Nat Immunol 2009 Apr;10(4):394-402.
- Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties.. Immunity 2003 Jul;19(1):71-82.
- Konopka JL, Penalva LO, Thompson JM, White LJ, Beard CW, Keene JD, Johnston RE. A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo.. PLoS Pathog 2007 Dec;3(12):e199.
- Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.. J Exp Med 1995 Aug 1;182(2):389-400.
- Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM. Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity.. J Intern Med 2012 Feb;271(2):183-92.
- Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines.. Immunol Rev 2008 Apr;222:256-76.
Citations
This article has been cited 13 times.- Loukinov D, Anderson AL, Mkrtichyan M, Ghochikyan A, Rivero-Hinojosa S, Tucker J, Lobanenkov V, Agadjanyan MG, Nelson EL. A Therapeutic Vaccine Targeting Rat BORIS (CTCFL) for the Treatment of Rat Breast Cancer Tumors.. Int J Mol Sci 2023 Mar 22;24(6).
- Su H, Imai K, Jia W, Li Z, DiCioccio RA, Serody JS, Poe JC, Chen BJ, Doan PL, Sarantopoulos S. Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens.. Front Immunol 2022;13:865486.
- Maruggi G, Ulmer JB, Rappuoli R, Yu D. Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action.. Curr Top Microbiol Immunol 2022;440:31-70.
- Maruggi G, Zhang C, Li J, Ulmer JB, Yu D. mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases.. Mol Ther 2019 Apr 10;27(4):757-772.
- Agnihothram S, Menachery VD, Yount BL Jr,, Lindesmith LC, Scobey T, Whitmore A, Schäfer A, Heise MT, Baric RS. Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform.. J Virol 2018 Jun 1;92(11).
- Zhao J, Zhao J, Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, Agnihothram S, Baric RS, David CS, Perlman S. Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses.. Immunity 2016 Jun 21;44(6):1379-91.
- Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE Jr. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.. Vaccine 2016 Feb 10;34(7):950-6.
- Beall A, Yount B, Lin CM, Hou Y, Wang Q, Saif L, Baric R. Characterization of a Pathogenic Full-Length cDNA Clone and Transmission Model for Porcine Epidemic Diarrhea Virus Strain PC22A.. mBio 2016 Jan 5;7(1):e01451-15.
- Lundstrom K. Alphavirus-based vaccines.. Viruses 2014 Jun 16;6(6):2392-415.
- Khalil SM, Tonkin DR, Snead AT, Parks GD, Johnston RE, White LJ. An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.. J Virol 2014 Aug;88(16):9182-96.
- Steil BP, Jorquera P, Westdijk J, Bakker WA, Johnston RE, Barro M. A mucosal adjuvant for the inactivated poliovirus vaccine.. Vaccine 2014 Jan 23;32(5):558-63.
- Zellweger RM, Miller R, Eddy WE, White LJ, Johnston RE, Shresta S. Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.. PLoS Pathog 2013 Oct;9(10):e1003723.
- Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.. Vaccine 2013 Feb 18;31(9):1298-304.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists